These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11041854)

  • 1. Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease.
    Ingallinella P; Bianchi E; Ingenito R; Koch U; Steinkühler C; Altamura S; Pessi A
    Biochemistry; 2000 Oct; 39(42):12898-906. PubMed ID: 11041854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
    Ingallinella P; Fattori D; Altamura S; Steinkühler C; Koch U; Cicero D; Bazzo R; Cortese R; Bianchi E; Pessi A
    Biochemistry; 2002 Apr; 41(17):5483-92. PubMed ID: 11969409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors.
    Bianchi E; Orrù S; Dal Piaz F; Ingenito R; Casbarra A; Biasiol G; Koch U; Pucci P; Pessi A
    Biochemistry; 1999 Oct; 38(42):13844-52. PubMed ID: 10529230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.
    Ingallinella P; Altamura S; Bianchi E; Taliani M; Ingenito R; Cortese R; De Francesco R; Steinkühler C; Pessi A
    Biochemistry; 1998 Jun; 37(25):8906-14. PubMed ID: 9636032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.
    Casbarra A; Piaz FD; Ingallinella P; Orrù S; Pucci P; Pessi A; Bianchi E
    Protein Sci; 2002 Sep; 11(9):2102-12. PubMed ID: 12192066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Product inhibition of the hepatitis C virus NS3 protease.
    Steinkühler C; Biasiol G; Brunetti M; Urbani A; Koch U; Cortese R; Pessi A; De Francesco R
    Biochemistry; 1998 Jun; 37(25):8899-905. PubMed ID: 9636031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
    De Francesco R; Pessi A; Steinkühler C
    Antivir Ther; 1998; 3(Suppl 3):99-109. PubMed ID: 10726060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of selective eglin inhibitors of HCV NS3 proteinase.
    Martin F; Dimasi N; Volpari C; Perrera C; Di Marco S; Brunetti M; Steinkühler C; De Francesco R; Sollazzo M
    Biochemistry; 1998 Aug; 37(33):11459-68. PubMed ID: 9708981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase.
    Attwood MR; Bennett JM; Campbell AD; Canning GG; Carr MG; Conway E; Dunsdon RM; Greening JR; Jones PS; Kay PB; Handa BK; Hurst DN; Jennings NS; Jordan S; Keech E; O'Brien MA; Overton HA; King-Underwood J; Raynham TM; Stenson KP; Wilkinson CS; Wilkinson TC; Wilson FX
    Antivir Chem Chemother; 1999 Sep; 10(5):259-73. PubMed ID: 10574181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
    Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel high throughput screening assay for HCV NS3 serine protease inhibitors.
    Berdichevsky Y; Zemel R; Bachmatov L; Abramovich A; Koren R; Sathiyamoorthy P; Golan-Goldhirsh A; Tur-Kaspa R; Benhar I
    J Virol Methods; 2003 Feb; 107(2):245-55. PubMed ID: 12505640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus NS3/4A protease.
    Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
    Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
    Bogen SL; Ruan S; Liu R; Agrawal S; Pichardo J; Prongay A; Baroudy B; Saksena AK; Girijavallabhan V; Njoroge FG
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1621-7. PubMed ID: 16387495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
    Landro JA; Raybuck SA; Luong YP; O'Malley ET; Harbeson SL; Morgenstern KA; Rao G; Livingston DJ
    Biochemistry; 1997 Aug; 36(31):9340-8. PubMed ID: 9235976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.
    Johansson A; Hubatsch I; Akerblom E; Lindeberg G; Winiwarter S; Danielson UH; Hallberg A
    Bioorg Med Chem Lett; 2001 Jan; 11(2):203-6. PubMed ID: 11206459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization.
    Koch U; Biasiol G; Brunetti M; Fattori D; Pallaoro M; Steinkühler C
    Biochemistry; 2001 Jan; 40(3):631-40. PubMed ID: 11170379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.